Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267942 | 0.93 | DDB1 (0.49) | DDB1CRBNGPR119MPOHPGD | |
| SCHEMBL26388949 | 0.93 | DDB1 (0.49) | DDB1CRBNGPR119MPOHPGD | |
| SCHEMBL15272945 | 0.92 | DDB1 (0.49) | DDB1CRBNGPR119MPOHPGD | |
| SCHEMBL23210804 | 0.88 | GPR119 (0.46) | DDB1CRBNGPR119HPGDRECQL | |
| SCHEMBL17122086 | 0.88 | MPO (0.45) | DDB1CRBNGPR119MPOHPGD | |
| SCHEMBL985090 | 0.87 | MPO (0.46) | DDB1CRBNGPR119MPOIRAK4 | |
| SCHEMBL16096491 | 0.86 | DDB1 (0.57) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL12121174 | 0.86 | DDB1 (0.57) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL16899840 | 0.85 | FGFR3 (0.43) | DDB1CRBNGPR119MPOHPGD | |
| SCHEMBL26388951 | 0.85 | FGFR3 (0.43) | DDB1CRBNGPR119MPOHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324790-A | Method for synthesizing crizotinib intermediate by photocatalysis | 江苏农牧科技职业学院 | 2024-07-12 | — | — | CN | claimed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118324790-A | Method for synthesizing crizotinib intermediate by photocatalysis | 江苏农牧科技职业学院 | 2024-07-12 | — | — | CN | disclosed |
| CN-118027041-A | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-113544130-B | BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| WO-2010068292-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-1786785-B1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20080300273-A1 | administering to mammal a therapeutically effective amount of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer mediated by an anaplastic lymphoma kinase | PFIZER INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300273-A1 | administering to mammal a therapeutically effective amount of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer mediated by an anaplastic lymphoma kinase | PFIZER INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300273-A1 | administering to mammal a therapeutically effective amount of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer mediated by an anaplastic lymphoma kinase | PFIZER INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080293769-A1 | Polymorphs of a C-Met/Hgfr Inhibitor | PFIZER INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293769-A1 | Polymorphs of a C-Met/Hgfr Inhibitor | PFIZER INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293769-A1 | Polymorphs of a C-Met/Hgfr Inhibitor | PFIZER INC. | 2008-11-27 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | DDB1 1072/4885CRBN 2867/4885GPR119 520/4885 |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | DDB1 919/4885CRBN 673/4885GPR119 1626/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | DDB1 1744/4885CRBN 669/4885GPR119 1204/4885 |
| US-20080300273-A1 | administering to mammal a therapeutically effective amount of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer mediated by an anaplastic lymphoma kinase | MET, HGF, HGFAC | DDB1 3227/4885CRBN 1771/4885GPR119 662/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | DDB1 1072/4885CRBN 2867/4885GPR119 520/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | DDB1 530/4885CRBN 1484/4885GPR119 2039/4885 |
| US-20080293769-A1 | Polymorphs of a C-Met/Hgfr Inhibitor | MET, HGF, HGFAC | DDB1 1218/4885CRBN 1945/4885GPR119 393/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | DDB1 1072/4885CRBN 2867/4885GPR119 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.